Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma

The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage op...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2018-10, Vol.35 (10), p.131-5, Article 131
Main Authors: Pender, Alexandra, Davis, Elizabeth J., Chauhan, Dharmisha, Messiou, Christina, Al-Muderis, Omar, Thway, Khin, Fisher, Cyril, Zaidi, Shane, Miah, Aisha, Judson, Ian, van der Graaf, Winette, Keedy, Vicki L., Benson, Charlotte, Jones, Robin L.
Format: Article
Language:English
Subjects:
Adult
Antimetabolites, Antineoplastic - administration & dosage
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Chemotherapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Female
Hematology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Oncology
Original Paper
Palliative Care - methods
Pathology
Retrospective Studies
Sarcoma
Sarcoma, Synovial - diagnosis
Sarcoma, Synovial - drug therapy
Sarcoma, Synovial - mortality
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, toxicity and outcome data were collected. Twenty one patients were treated with gemcitabine/docetaxel, the majority as a second- or third-line treatment for metastatic disease. The response rate was 5% with a median progression-free survival of 2 months (95% CI 1.3–3.7). Toxicities reported were as expected for this chemotherapy combination. Treatment was not discontinued due to toxicity. Gemcitabine/docetaxel chemotherapy shows little efficacy in synovial sarcoma and should not be offered to this patient group outside a clinical trial context.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-018-1193-5